Overview
Orphinic Scientific is a biopharma holding focused on the clinical development of projects in therapeutics, MedTech and e-Health. Its portfolio includes an enhanced analgesic formulation, a therapeutic mechanism for diastolic heart failure, and a software solution designed to automate clinical trial monitoring. The company verifies research hypotheses through clinical trials and partners or transacts assets with pharmaceutical players.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
1 of 5 financial statements was filed late (for 2021, 97 days late). All were audited by a statutory auditor.
- 2025filed
- 202404/07/2025
- 202310/07/2024
- 202213/07/2023
- 202120/10/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Clinical trials
- Drug development
- Therapy development
- Medtech projects
- Clinical trial monitoring software
Websites
- orphinic.comOrphinic Scientific
- orphinic.plOrphinic Scientific
Job offers
The company lists 2 job openings on its own careers page: orphinic.com/career.
Authorized Representatives
Manner of representation
In the case of a one-person management board, the company is represented by the sole member of the management board. If the management board is multi-member, two members of the management board jointly or one member of the management board jointly with a commercial proxy are authorised to make declarations of will and sign on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
Bank accounts
Registered as a VAT taxpayer on 2020-09-01.
95 2490 0005 0000 4600 1201 8277
68 2490 0005 0000 4530 3477 6850
03 2490 0005 0000 4600 8737 7972
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 11, 2025 | Commercial Companies Code notice | |
| Sep 2, 2024 | Commercial Companies Code notice |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Pharmaxi Poland sp. z o.o. | $152,292.34 | pharmaxi.com.ua | ||
| New Value sp. z o.o. | $64,335.86 | new-value.pl | ||
| Biostat Research and Development sp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Robotic Medical Solutions sp. z o.o. | $47,979.94 | roboticmedicalsolutions.com | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl | ||
| Just Be Innovative sp. z o.o. | $32,662.40 | justbeinnovative.com | ||
| DR Joanna Sanford sp. k. | $28,674.82 | sanfordbiotech.com | ||
| Nanovelos S.A. | $24,842.03 | nanovelos.com | ||
| Medai sp. z o.o. | $22,311.83 | medai.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-09 | Address change (Ul. Postępu 21b, 02-676, Warszawa → Ul. Stanisława Żaryna 2b, 02-593, Warszawa) | |
| 2026-04-09 | Share capital increase (440,562.80 PLN → 506,090.90 PLN) | |
| 2025-04-28 | Share capital increase (438,542.50 PLN → 440,562.80 PLN) | |
| 2025-02-18 | Share capital increase (435,149.30 PLN → 438,542.50 PLN) | |
| 2024-12-11 | Share capital increase (421,815.90 PLN → 435,149.30 PLN) |
FAQ
Last updated: 2026-04-09